VIDEO: Updates on menin inhibitors for acute myeloid leukemia from SOHO Annual Meeting
Click Here to Manage Email Alerts
Healio spoke with Naval Daver, MD, about presentations on the use of molecular therapies, including menin inhibitors, in the treatment of acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.
“In acute myeloid leukemia especially, there were a lot of updates on molecular therapies. Probably the number 1 among them is the menin inhibitors,” Daver, professor and director of the Leukemia Research Alliance Program in the department of leukemia at The University of Texas MD Anderson Cancer Center, said. “These agents have been showing very effective outcomes in patients with relapse/refractory AML, especially those with KMT2A rearrangement or NPM1 mutation.”
He noted that during her presentation, Eunice Wang, MD, chief of leukemia service at Roswell Park Comprehensive Cancer Center, discussed the latest information on menin inhibitors, including ongoing trials assessing the use of these inhibitors as a single agent or part of a combination therapy.
“We are hoping that we may be seeing some of these menin inhibitors approved in the near future,” Daver said. “They are under FDA review at this time.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts